NFKB1 and metabolic dysfunction-associated steatotic liver disease: The therapeutic action of AR arises from its regulation of five core targets (PPARA, NFKB1, IL6, AKT1, and IL1B) and six key signaling pathways (PPAR, AGE-RAGE, IR, NAFLD, TNF, and IL-17 signaling pathways), as well as its modulation of linoleic acid metabolism.